Formation of gadolinium–ferritin from clinical magnetic resonance contrast agents

Jitka Neburkova; Aaron M. Rulseh; Shery L. Y. Chang; Helena Raabova; Jana Vejpravova; Martin Dracinsky; Jan Tarabek; Jan Kotek; Mohan Pingle; Pavel Majer; Josef Vymazal; Petr Cigler

doi:10.1039/C9NA00567F

Formation of gadolinium–ferritin from clinical magnetic resonance contrast agents†

Jitka Neburkova,

^a Aaron M. Rulseh,

^b Shery L. Y. Chang,

^c Helena Raabova,^a Jana Vejpravova,

^de Martin Dracinsky,

^a Jan Tarabek,

^a Jan Kotek,

^d Mohan Pingle,^b Pavel Majer,^a Josef Vymazal

*^b and Petr Cigler

*^a

Author affiliations

* Corresponding authors

^a Institute of Organic Chemistry and Biochemistry of the CAS, Flemingovo nam. 2, Prague, Czechia
E-mail: cigler@uochb.cas.cz

^b Department of Radiology, Na Homolce Hospital, Roentgenova 2, Prague, Czechia
E-mail: josef.vymazal@volny.cz

^c Electron Microscopy Unit, Mark Wainwright Analytical Centre, and School of Materials Science and Engineering, University of New South Wales, Sydney, NSW 2052, Australia

^d Department of Inorganic Chemistry, Faculty of Science, Charles University, Hlavova 8, 128 43 Prague 2, Czechia

^e Department of Condensed Matter Physics, Faculty of Mathematics and Physics, Charles University, Ke Karlovu 5, 121 16 Prague 2, Czechia

Abstract

Gadolinium deposition in the brain following administration of gadolinium-based contrast agents (GBCAs) has led to health concerns. We show that some clinical GBCAs form Gd³⁺–ferritin nanoparticles at (sub)nanomolar concentrations of Gd³⁺ under physiological conditions. We describe their structure at atomic resolution and discuss potential relevance for clinical MRI.

Nanoscale Advances

Formation of gadolinium–ferritin from clinical magnetic resonance contrast agents†

Abstract

Supplementary files

Article information

Download Citation

Permissions

Formation of gadolinium–ferritin from clinical magnetic resonance contrast agents

Social activity

Search articles by author

Spotlight

Advertisements